<DOC>
	<DOCNO>NCT00142831</DOCNO>
	<brief_summary>Existing new pharmacotherapies along prevention effort key improve smoke cessation rate reduce premature morbidity mortality associate tobacco use . A number individual suffer nicotine dependence depression . The purpose study determine effectiveness bupropion use combination nicotine replacement patch cognitive behavior therapy ( CBT ) treat nicotine dependent individual also diagnose depression .</brief_summary>
	<brief_title>Bupropion Adjunct Nicotine Patch Plus CBT</brief_title>
	<detailed_description>Smoking cessation treatment highly cost effective pharmacotherapy universally recommend treatment nicotine dependence . However , majority smoker unable quit even treatment . Existing new pharmacotherapies along prevention effort key improve smoke cessation rate reduce premature morbidity mortality associate tobacco use . The purpose study examine effectiveness bupropion addition standard smoke cessation treatment CBT nicotine replacement . In addition , study determine bupropion improve individual 's odds quit smoking , whether achieve impact negative mood state associate depression . Participants double-blind study randomly assign receive either bupropion placebo . CBT session individual meeting study physician last 13 week . Treatment either bupropion placebo begin first CBT meeting continue 13 week . Treatment nicotine replacement patch begin second CBT meeting continue 10 week . Participants monthly follow-up visit throughout year follow Week 13 . During follow-up period , participant continue take either bupropion placebo longer undergo CBT nicotine replacement . If participant unable quit smoking , become depressed follow-up phase , offer treatment Zoloft , continue monitor duration follow-up year . If participant unsuccessful use Zoloft , offer another antidepressant judgement clinician .</detailed_description>
	<mesh_term>Tobacco Use Disorder</mesh_term>
	<mesh_term>Nicotine</mesh_term>
	<mesh_term>Bupropion</mesh_term>
	<criteria>Smokes least 10 cigarette per day least past 2 year Meets DSMIV criterion nicotine dependence , determine Fagerstrom Nicotine Tolerance Questionnaire Meets DSMIV diagnose unipolar depressive disorder ( major depression , dysthymia , minor depression ) Current suicidal homicidal risk Serious illness , include cardiovascular , liver , kidney , respiratory , endocrine , neurologic , hematologic disease Untreated peptic ulcer Lifethreatening arrhythmia , cerebrovascular , cardiovascular event within 6 month prior enrollment Severe respiratory compromise , define FEV1 le 1.0 L/min and/or pO2 le 60 pCO2 less 45 Currently use nicotinecontaining product ( e.g. , cigar , pipe , snuff , nicotine gum ) History seizure disorder Current DSMIV diagnosis organic mental disorder , schizophrenia , delusional disorder , psychotic disorder , bipolar disorder , antisocial personality disorder Current DSMIV diagnosis substance abuse dependence disorder within year prior enrollment Current eating disorder , include anorexia nervosa bulimia nervosa History multiple adverse drug reaction allergy bupropion Mood congruent mood incongruent psychotic feature Current use psychotropic drug ( exception hypnotic benzodiazepine stable dos least six month prior enrollment current use nonbenzodiazepine hypnotic Ambien Sonata ) Clinical laboratory evidence hypothyroidism Currently seek treatment smoke cessation History skin disease ( e.g. , psoriasis ) , skin allergy , strong reaction topical preparation , medical dressing , tape Currently use topical drug Pregnant Not use adequate method contraception</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2008</verification_date>
	<keyword>nicotine dependence</keyword>
</DOC>